Your AI-Trained Oncology Knowledge Connection!

The Evolving Treatment Paradigm in Multiple Myeloma: Recent Updates : Episode 16

Video

August 8, 2023

Multiple Myeloma: Unmet Needs and Future Directions in Care

Author(s):

Joshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB

After discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.

EP: 1.What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?

EP: 2.NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy

EP: 3.Induction Therapy Regimens for Transplant-Eligible NDMM

EP: 4.Impact of Risk Status on Treatment Pathways in Newly Diagnosed Multiple Myeloma

EP: 5.Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma

EP: 6.Determining Frailty in Patients With Newly Diagnosed Multiple Myeloma

EP: 7.Treatment Duration in Patients With Newly Diagnosed Multiple Myeloma

EP: 8.Patient Scenario: Treatment Options in MM at First Relapse

EP: 9.Factors in Selecting Therapy at First Relapse in Multiple Myeloma

EP: 10.Patient Scenario: Bispecifics in MM After Multiple Prior Lines of Therapy

EP: 11.Multiple Myeloma: Sequencing Novel Therapies in Later Lines of Treatment

EP: 12.Bispecifics in Multiple Myeloma: Dosing and Transition of Care

EP: 13.Combination Strategies With Bispecifics in Multiple Myeloma

EP: 14.Bispecifics in Multiple Myeloma: Adverse Event Management

EP: 15.CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond

Now Viewing

EP: 16.Multiple Myeloma: Unmet Needs and Future Directions in Care

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

May 14th 2025 - May 15th 2026

online-activity

Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

May 13th 2025 - Jun 18th 2025

online-activity

Video

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

May 9th 2025 - Jun 14th 2025

online-activity

Latest Conference Coverage

Analysis of PADA-1 Trial Highlights Kinetics and Determinants of ESR1 Mutations in HR+/HER2– Metastatic Breast Cancer

OncLive Polls Spotlight Phase 3 Breast Cancer Studies Generating Buzz Ahead of ASCO 2025

Ribociclib/Endocrine Therapy Yields Similar pCRs Compared With Chemotherapy in HR+ Early Breast Cancer

Emiltatug Ledadotin Shows Early Clinical Activity and Safety in Advanced/Metastatic TNBC

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Multiple Myeloma: Unmet Needs and Future Directions in Care

EP: 1.What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?

EP: 2.NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy

EP: 3.Induction Therapy Regimens for Transplant-Eligible NDMM

EP: 4.Impact of Risk Status on Treatment Pathways in Newly Diagnosed Multiple Myeloma

EP: 5.Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma

EP: 6.Determining Frailty in Patients With Newly Diagnosed Multiple Myeloma

EP: 7.Treatment Duration in Patients With Newly Diagnosed Multiple Myeloma

EP: 8.Patient Scenario: Treatment Options in MM at First Relapse

EP: 9.Factors in Selecting Therapy at First Relapse in Multiple Myeloma

EP: 10.Patient Scenario: Bispecifics in MM After Multiple Prior Lines of Therapy

EP: 11.Multiple Myeloma: Sequencing Novel Therapies in Later Lines of Treatment

EP: 12.Bispecifics in Multiple Myeloma: Dosing and Transition of Care

EP: 13.Combination Strategies With Bispecifics in Multiple Myeloma

EP: 14.Bispecifics in Multiple Myeloma: Adverse Event Management

EP: 15.CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond

EP: 16.Multiple Myeloma: Unmet Needs and Future Directions in Care

Newsletter

Latest CME

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Latest Conference Coverage